joint imaging (using standardized methods for taking and rating radiographs, or any demonstrably superior imaging technique) for studies of 1 yr or longer.
Quality of life anduor utility measures are also strongly recommended, but further work should be carried out to assess the usefulness of biological markers, stiffness, measures of inflammation and other assessments such as performance-based measures, time to surgery, flares or analgesic consumption before they are accepted as core measures.
Outcome measures for ankylosing spondylitis
This core set of endpoints in ankylosing spondylitis clinical trials was developed at OMERACT 4 and published in the Journal of Rheumatology w4x. Defined core sets have been developed for use in four settings: disease-controlling anti-rheumatic therapy (DC-ART), symptom-modifying anti-rheumatic drugs (SM-ARD) and physical therapy, and for clinical record keeping. These are as follows: 
Outcomes measures for systemic lupus erythematosus
A core set of outcome measures and response criteria were developed during OMERACT 4 and published in the Journal of Rheumatology w5, 6x.
The core outcome domains to be measured in both randomized clinical trials and longitudinal observation studies in systemic lupus erythematosus are: disease activity health-related quality of life damage toxicityuadverse events.
Outcome measures for osteoporosis
The core endpoints for osteoporosis trials were discussed at OMERACT 3 and subsequently published in the Journal of Rheumatology w7x.
The outcome measures for osteoporosis trials were discussed according to two broad groupings of trials: randomized trials where prevention of rapid bone loss was the primary aim and randomized trials where prevention of fractures may be a feasible outcome because patients were already at high risk of osteoporotic fractures either on the basis of low bone mass or previous osteoporotic fracture.
Randomized trials where prevention of rapid bone loss was the primary aim Two core outcome measures of clinical benefit were considered appropriate:
(a) bone minimum density (measured at two sites:
the lumbar spine and proximal femur); (b) biochemical markers which should include at least one resorption marker (which should be based on a urinary cross-linked excretion) and at least one formation marker.
Non-core outcome measures of clinical benefit were considered to be:
(a) fractures; (b) quality of life; (c) change in height (measured in a standardized manner).
Randomized trials of fracture prevention in high-risk populations
The core outcome measures of benefit were:
(a) fracture; (b) hip and spine bone mineral density; (c) biochemical markers; (d) change in height.
The non-core outcome measures of benefit in these studies would include:
(a) quality of life instrument; (b) back pain measure; (c) economic evaluation, including health service utilization such as hospitalization, cotherapy, etc.; (d) measure of incident falls.
It was recommended that these studies should be of 3-5 yr duration.
Criteria for the classification of rheumatic diseases

Ankylosing spondylitis
The 1961 Rome criteria for ankylosing spondylitis w8x
Low back pain and stiffness for more than 3 months not relieved by rest; Pain and stiffness of the thoracic region;
Limited motion in lumbar spine; Limited chest expansion; Evidence or history of iritis or its sequelae.
Requirements: either positive radiographs (bilateral SI) and one or more clinical criteria, or four out of five clinical criteria.
The 1966 New York criteria for ankylosing spondylitis w9x
(1) Presence of history of pain at dorsolumbar junction or in lumbar spine; (2) Limitation of motion in anterior flexion, lateral flexion and extension; (3) Limitation of chest expansion to 1 inch (2.5 cm) or less at the fourth intercostal space. a History of allergy, other than asthma or drug-related, is included only in the tree classification criteria set and not in the traditional format criteria set, which requires four or more of the six other items listed here.
Fibromyalgia w14x
History of widespread pain
Definition: Pain is considered widespread when all of the following are present: pain in the left side of the body, pain in the right side of the body, pain above the waist, and pain below the waist. In addition, axial skeletal pain (cervical spine or anterior chest or thoracic spine or low back) must be present. In this definition, shoulder and buttock pain is considered as pain for each involved. 'Low back' pain is considered lower segment pain.
Pain in 11 of 18 tender point sites on digital palpation Definition: Pain, on digital palpation, must be present in at least 11 of the following 18 tender point sites:
occiput-bilateral, at the suboccipital muscle insertions; low cervical-bilateral, at the anterior aspects of the intertransverse spaces at C5-C7; trapezius-bilateral, at the midpoint of the upper border; supraspinatus-bilateral, at origins, above the scapula spine near the medial border; second rib-bilateral, at the second costochondral junctions, just lateral to the junctions on upper surfaces; lateral epicondyle-bilateral, 2 cm distal to the epicondyles; gluteal-bilateral, in upper outer quadrants of buttocks in anterior fold of muscle; knee-bilateral, at the medial fat pad proximal to the joint line.
Digital palpation should be performed with an approximate force of 4 kg.
For a tender point to be considered 'positive' the subject must state that the palpation was painful. 'Tender' is not to be considered 'painful'.
For classification purposes, patients will be said to have fibromyalgia if both criteria are satisfied. Widespread pain must have been present for at least 3 months. The presence of a second clinical disorder does not exclude the diagnosis of fibromyalgia.
Giant cell arteritis w15x
The 1990 criteria for the classification of giant cell (temporal) arteritis (traditional format) 
hard tissue enlargement of two or more of 10 selected joints; hard tissue enlargement of two or more distal interphalangeal joints; fewer than three swollen metacarpophalangeal (MCP) joints; deformity of at least one of 10 selected joints.
The 10 selected joints are the second and third distal interphalangeal, the second and third proximal interphalangeal (PIP), and the first carpometacarpal joints of both hands. This classification method yields a sensitivity of 94% and a specificity of 87%.
Osteoarthritis of the hip w21x
Combined clinical (history, physical examination, laboratory) and radiographic classification criteria for osteoarthritis of the hip (traditional format) Hip pain and at least two of the following three features: erythrocyte sedimentation rate < 20 mmuh; radiographic femoral or acetabular osteophytes; radiographic joint space narrowing (superior, axial, anduor medial).
This classification method yields a sensitivity of 89% and a specificity of 91%.
Combined clinical (history, physical examination, laboratory) and radiographic classification criteria for osteoarthritis of the hip (classification tree format) Hip pain and Femoral anduor acetabular osteophytes on radiograph or Erythrocyte sedimentation rate ( 20 mmuh and Axial joint space narrowing on radiograph This classification method yields a sensitivity of 91% and a specificity of 89%.
Osteoarthritis of the knee w22x
Criteria for the classification of idiopathic osteoarthritis of the knee A patient is said to have dermatomyositis if at least one item from (1) and at least four items from (2) to (9) are present. The sensitivity is 94.1% (127u135), and the specificity of skin lesions against systemic lupus erythematosus and systemic sclerosis is 90.3% (214u237). A patient is said to have polymyositis if at least four items from (2) to (9) Laboratory findings: elevated acute-phase reactants erythrocyte sedimentation rate C-reactive protein prolonged PR interval Supporting evidence of antecedent group A streptococcal infections Positive throat culture or rapid streptococcal antigen test Elevated or rising streptococcal antibody titre If supported by evidence of preceding group A streptococcal infection, the presence of two major manifestations or of one major and two minor manifestations indicates a high probability of acute rheumatic fever.
Rheumatoid arthritis w28x
The 1987 Demonstration of abnormal amounts of serum rheumatoid factor by any method for which the result has been positive in <5% of normal control subjects (7) Radiographic changes Radiographic changes typical of rheumatoid arthritis on posteroanterior hand and wrist radiographs, which must include erosions or unequivocal bony decalcification localized in or most marked adjacent to the involved joints (osteoarthritis changes alone do not qualify)
For classification purposes, a patient shall be said to have rheumatoid arthritis if heushe has satisfied at least four of these seven criteria. Criteria (1)- (4) 
Systemic sclerosis w33x
American Rheumatism Association Scleroderma Criteria Cooperative Study (SCCS): preliminary clinical criteria for systemic sclerosis (excludes localized scleroderma and pseudosclerodermatous disorders) Proximal scleroderma is the single major criterion; sensitivity was 91% and specificity was over 99%.
Sclerodactyly, digital pitting scars of fingertips or loss of substance of the distal finger pad, and bibasilar pulmonary fibrosis contributed further as minor criteria in the absence of proximal scleroderma.
One major or two or more minor criteria were found in 97% of definite systemic sclerosis patients, but only in 2% of the comparison patients with systemic lupus erythematosus, polymyositisudermatomyositis, or Raynaud's phenomenon.
Takayasu's arteritis w34x
The 1990 criteria for the classification of Takayasu's arteritis (traditional format) 
